Healthcare
VIA Pharmaceuticals, Inc.(VIAP)
Live Price
Offline$0.0005
+0.00% today
1Y Change
-0.00%
Window
Jun 23, 2025 → Jun 11, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +55.2%
- Dividend Yield
- 0.0%
Coverage: 241 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VIA Pharmaceuticals, Inc. (VIAP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 0.0% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +55.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +55.2%, free cash flow +48.6% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines VIAP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +55.2%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIAP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIAP Max Drawdown
-0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VIAP and SPY.
Company Overview
VIA Pharmaceuticals, Inc.
Other OTC
VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.
- Leadership
- Thomas Quertermous
- IPO Date
- Jun 6, 2007
- Employees
- 6
- Street Address
- 750 Battery Street
- Mailing
- San Francisco
- Region
- San Francisco, US
- Reporting Currency
- USD
- Investor Line
- +1 415 283 2200
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +55.2%
- Free Cash Flow
- +48.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 64.7%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.